Literature DB >> 26258761

Attitudes to Alzheimer's disease testing of Australian general practice patients: a cross-sectional questionnaire-based study.

Parker Magin1,2, Laura Juratowitch1, Janet Dunbabin1, Patrick McElduff1, Susan Goode1, Amanda Tapley2, Dimity Pond1.   

Abstract

OBJECTIVE: In view of proposed screening for presymptomatic Alzheimer's disease (AD) with advanced imaging, and blood and cerebral spinal fluid analysis, we aimed to establish levels, and associations, of acceptance of AD testing modalities by general practice patients.
METHODS: A cross-sectional questionnaire-based study of consecutive patients (aged 50 years and over) of general practices of an Australian practice-based research network was used. The questionnaire elicited demographic data and attitudes to screening for other diseases and included the screening acceptance domain of the Perceptions Regarding Investigational Screening for Memory in Primary Care (PRISM-PC) instrument. This assesses receptivity to modalities of testing for AD: short questionnaire, blood test, cerebral imaging, and annual physician examination. Reflecting speculation of possible future AD diagnostic methods, an item regarding testing cerebral spinal fluid was also included. Associations of PRISM-PC scores were analyzed with multiple linear regression.
RESULTS: Of 489 participants (response rate 87%), 66.2% would like to know if they had AD. Participants were more accepting of testing modalities that were noninvasive or familiar (questionnaire, physician's examination, and blood test) as opposed to cerebral imaging or lumbar puncture. Attitudes to AD testing are influenced by a positive attitude to disease screening in general. Patients with a self-perceived higher risk of AD were less accepting of testing, as were participants with an educational level of junior high school (10 school years) or less.
CONCLUSIONS: This study demonstrates that a majority of patients would like to know if they have AD. Acceptability of testing modalities, however, varies. Noninvasive, familiar methods are more acceptable.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Alzheimer's disease; attitude to health; dementia; early diagnosis; general practice; invasive testing

Mesh:

Year:  2015        PMID: 26258761     DOI: 10.1002/gps.4335

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  5 in total

Review 1.  2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.

Authors:  A Leuzy; N J Ashton; N Mattsson-Carlgren; A Dodich; M Boccardi; J Corre; A Drzezga; A Nordberg; R Ossenkoppele; H Zetterberg; K Blennow; G B Frisoni; V Garibotto; O Hansson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-03-05       Impact factor: 9.236

Review 2.  A Systematic Review of Longitudinal Studies Which Measure Alzheimer's Disease Biomarkers.

Authors:  Emma Lawrence; Carolin Vegvari; Alison Ower; Christoforos Hadjichrysanthou; Frank De Wolf; Roy M Anderson
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

3.  Fear and Uncertainty Do Not Influence Reported Willingness to Undergo Lumbar Punctures in a U.S. Multi-Cultural Cohort.

Authors:  Dobromira Z Tsvetkova; Sharon H Bergquist; Monica W Parker; Thomas L Jarrett; Jennifer C Howell; Kelly D Watts; Alexander Kollhoff; David L Roberts; William T Hu
Journal:  Front Aging Neurosci       Date:  2017-02-10       Impact factor: 5.750

4.  Experiences of dementia and attitude towards prevention: a qualitative study among older adults participating in a prevention trial.

Authors:  Anna Rosenberg; Nicola Coley; Alexandra Soulier; Jenni Kulmala; Hilkka Soininen; Sandrine Andrieu; Miia Kivipelto; Mariagnese Barbera
Journal:  BMC Geriatr       Date:  2020-03-12       Impact factor: 3.921

5.  What is a 'timely' diagnosis? Exploring the preferences of Australian health service consumers regarding when a diagnosis of dementia should be disclosed.

Authors:  Rochelle Watson; Jamie Bryant; Robert Sanson-Fisher; Elise Mansfield; Tiffany-Jane Evans
Journal:  BMC Health Serv Res       Date:  2018-08-06       Impact factor: 2.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.